News - Advair, Kyorin Pharmaceuticals

Filter

Popular Filters

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Flutiform recommended for approval in Japan

01-08-2013

UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin

05-04-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with venture capital…

AmbrxAstellas PharmaKyorin PharmaceuticalsLicensingMergers & AcquisitionsOncologyPharmaceuticalTeijin

Great expectations for GlaxoSmithKline R&D newsflow

13-12-2012

Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant…

AdvairdarapladibFinancialGlaxoSmithKlineMAGE-A3PharmaceuticalResearch

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26-11-2012

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

Kyorin Pharma transfers Pekiron rights to Galderma

11-10-2012

Japan's Kyorin Holdings (TYO: 4569), through its Kyorin Pharmaceuticals subsidiary, aiming to concentrate…

Asia-PacificDermatologicalsGaldermaKyorin PharmaceuticalsLicensingPekironPharmaceutical

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

SkyePharma partner Kyorin files for Flutiform approval in Japan

26-09-2012

UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma partner Kyorin completes Japanese Flutiform clinical program

26-06-2012

UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Relovair COPD and asthma filings on track despite more mixed trial results

26-03-2012

As well as announcing new mixed clinical trial data, UK pharma giant GlaxoSmithKline (LSE: GSK) and US…

AdvairEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRelovairRespiratory and PulmonaryTheravance

Back to top